IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma

Cancer Science

Volumn 103, Issue 2, 2012, Pages 269-273

  Songtao, Qi ^a   Lei, Yu ^a   Si, Gui ^b   Yanqing, Ding ^a   Huixia, Han ^a   Xuelin, Zhang ^a   Lanxiao, Wu ^c   Fei, Yao ^c  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^c Helixgen (Guangzhou) Biotech Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

6 O METHYLGUANINE; DNA METHYLTRANSFERASE; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; PROTEIN P53; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SIZE; CANCER SURVIVAL; CHEMOSENSITIVITY; CHROMOSOME 1P; DISEASE ASSOCIATION; DNA METHYLATION; FEMALE; GENE DELETION; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BASE SEQUENCE; BRAIN NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; FEMALE; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84856466311     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02134.x     Document Type: Article

References (34)

1. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005; 64: 479-89.
2. Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64: 6892-9.
3. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170: 1445-53.
4. Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-4.
5. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
6. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
7. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-66.
8. Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 2009; 100: 2235-41.
9. Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-12.
10. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008; 116: 597-602.
11. Hartmann C, Meyer J, Balss J et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1, 010 diffuse gliomas. Acta Neuropathol 2009; 118: 469-74.
12. Ichimura K, Pearson DM, Kocialkowski S et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009; 11: 341-7.
13. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009; 174: 1149-53.
14. Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-73.
15. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009; 15: 6002-7.
16. Sanson M, Marie Y, Paris S et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009; 27: 4150-4.
17. Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol 2011; 12: 83-91.
18. Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 2010; 102: 932-41.
19. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
20. Reed GH, Kent JO, Wittwer CT. High-resolution DNA melting analysis for simple and efficient molecular diagnostics. Pharmacogenomics 2007; 8: 597-608.
21. Reddy KS. Assessment of 1p/19q deletions by fluorescence in situ hybridization in gliomas. Cancer Genet Cytogenet 2008; 184: 77-86.
22. Macdonald DR, Cascino TL, Schold SJ, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-80.
23. Houillier C, Wang X, Kaloshi G et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010; 75: 1560-6.
24. Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 2009; 22: 633-8.
25. Mueller W, Hartmann C, Hoffmann A et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002; 161: 313-9.
26. Riemenschneider MJ, Hegi ME, Reifenberger G. MGMT promoter methylation in malignant gliomas. Target Oncol 2010; 5: 161-5.
27. Herrlinger U, Rieger J, Koch D et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 2006; 24: 4412-7.
28. Weller M, Felsberg J, Hartmann C et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27: 5743-50.
29. Sadones J, Michotte A, Veld P et al. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer 2009; 45: 146-53.
30. Wick W, Hartmann C, Engel C et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27: 5874-80.
31. van den Bent MJ, Dubbink HJ, Sanson M et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 2009; 27: 5881-6.
32. Rivera AL, Pelloski CE, Gilbert MR et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 2010; 12: 116-21.
33. van den Bent MJ, Dubbink HJ, Marie Y et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010; 16: 1597-604.
34. Ward PS, Patel J, Wise DR et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225-34.